Perceptive Capital Solutions Corp Overview
Pro stress-test →Perceptive Capital Solutions Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. PCSC's sponsor is an affiliate of Perceptive Advisors, a leading life sciences focused investment firm.
Strategic Profile
Pro stress-test →Freenome and Perceptive Capital Solutions Corp announced a business combination agreement (December 5, 2025) to create a publicly listed company transforming blood-based multi-cancer detection through an AI/ML-enabled multiomics platform. The registration statement was declared effective by the SEC on June 17, 2026, with an Extraordinary General Meeting of shareholders scheduled for July 9, 2026. Upon closing, PCSC will be renamed Freenome, Inc. and trade under ticker symbol FRNM on Nasdaq.
Competitive Landscape
Pro stress-test →Freenome will compete with established cancer diagnostics providers including Guardant Health (Guardant360), Foundation Medicine (FoundationOne), and emerging liquid biopsy companies like GRAIL (acquired by Illumina). The competitive advantage lies in Freenome's multiomics platform and institutional backing, though execution risk and regulatory pathway clarity remain material.
Industry Context
Perceptive Capital Solutions Corp operates in Blood-based cancer diagnostics.
Key facts
Founded: 2024 · Headquarters: New York, US · Employees: N/A · Revenue: N/A · Market cap: N/A